Pharmaceutical And Food Production Expansions Will Unlock Future Opportunities

Published
08 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$1,276.36
3.7% overvalued intrinsic discount
14 Aug
US$1,324.06
Loading
1Y
-5.6%
7D
8.4%

Author's Valuation

US$1.3k

3.7% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 0.89%

Shared on30 Apr 25
Fair value Increased 1.94%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 3.79%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 1.53%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.64%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 0.45%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 0.22%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 4.88%

AnalystConsensusTarget has decreased revenue growth from 4.6% to 4.0%.